Drug Trial Radar · NCT03018730
Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
May 17, 2017
Primary completion
Dec 17, 2019
Study completion Jan 9, 2020
Sponsor
- Lead sponsor
- ProtalixIndustry
- Sponsor type
- Industry
- Collaborators
- Chiesi Farmaceutici S.p.A.
- First posted
- Jan 12, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label switch over study to assess the safety and efficacy of PRX-102 (pegunigalsidase alfa). Patients treated with agalsidase alfa for at least 2 years and on a stable dose (\>80% labelled dose/kg) for at least 6 months. Patients will be screened and evaluated over 3 months while continuing on agalsidase alfa. Following the screening period, the patient will be enrolled and switched from their agalsidase alfa treatment to receive intravenous (IV) infusions of PRX-102 1 mg/kg every two weeks for 12 months. No more than 25% of treated patients will be female.
Conditions
- Fabry Disease
Interventions
PRX-102 (pegunigalsidase alfa)Biological
PRX-102 1 mg/kg every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03Time frame: 12 months
Locations
9 sites in 7 countries. Site status is shown where the registry gives one.
Royal Melbourne Hospital
Parkville, Victoria, Australia
Capital Health
Halifax, Nova Scotia, Canada
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
Academisch Medisch Centrum
Amsterdam, Netherlands
Helse Bergen HF Haukeland Universitetssykehus
Bergen, Norway
General Hospital Slovenj Gradec
Slovenj Gradec, Slovenia
The Royal Free Hospital
London, United Kingdom
Salford Royal NHS Foundation Trust
Salford, United Kingdom
Queen Elizabeth Hospital, Department of Neurology,
Edgbaston, Birmingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.